Please try another search
YTD | 3M | 1Y | 3Y | 5Y | 10Y | |
---|---|---|---|---|---|---|
Growth of 1000 | 1089 | 1062 | 1086 | 1060 | 1405 | 1988 |
Fund Return | 8.92% | 6.19% | 8.56% | 1.96% | 7.04% | 7.12% |
Place in category | 237 | 379 | 176 | 323 | 102 | 34 |
% in Category | 37 | 57 | 29 | 59 | 24 | 12 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Pictet CH Institutional Swiss EquZD | 1.74B | 9.13 | 2.44 | 7.62 | ||
Pictet CH Institutional Swiss EquiP | 1.74B | 8.83 | 1.75 | 6.90 | ||
Pictet CH Institutional Swiss EquPD | 1.74B | 2.54 | 3.57 | 6.65 | ||
Pictet CH Institutional Swiss EquiZ | 1.74B | 2.66 | 4.28 | 7.37 | ||
Pictet CH Institutional Swiss EquID | 1.74B | 2.58 | 3.78 | 6.87 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
CH0033782431 | 2.49B | 3.85 | 3.74 | 6.24 | ||
Raiffeisen Futura Swiss Stock A | 2.2B | 2.12 | 2.41 | 6.12 | ||
UBS CH Equity Fund Swiss Income CHF | 1.85B | 2.43 | 3.56 | 5.81 | ||
UBS CH Equity Fund Swiss Income CHQ | 1.85B | 2.59 | 4.20 | 6.41 | ||
UBAM Swiss Equity AD CHF Inc | 1.79B | 7.99 | -0.55 | 5.90 |
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
Nestle | CH0038863350 | 14.94 | 98.02 | -0.33% | |
Roche Holding Participation | CH0012032048 | 11.10 | 242.60 | +1.89% | |
Novartis | CH0012005267 | 10.15 | 94.95 | -0.04% | |
Richemont | CH0210483332 | 5.77 | 150.45 | +0.84% | |
ABB | CH0012221716 | 5.33 | 50.26 | -0.71% |
Type | Daily | Weekly | Monthly |
---|---|---|---|
Moving Averages | Buy | Buy | Buy |
Technical Indicators | Strong Buy | Strong Buy | Strong Buy |
Summary | Strong Buy | Strong Buy | Strong Buy |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review